SAB Biotherapeutics, Inc. (NASDAQ:SABS) Shares Sold by RTW Investments LP

RTW Investments LP decreased its position in SAB Biotherapeutics, Inc. (NASDAQ:SABS) by 17.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 635,276 shares of the company’s stock after selling 131,670 shares during the quarter. RTW Investments LP owned 6.88% of SAB Biotherapeutics worth $1,715,000 at the end of the most recent quarter.

Separately, First PREMIER Bank acquired a new stake in SAB Biotherapeutics in the second quarter valued at approximately $60,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Stock Performance

NASDAQ:SABS opened at $2.89 on Thursday. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09. SAB Biotherapeutics, Inc. has a 52-week low of $2.16 and a 52-week high of $9.09. The stock has a fifty day simple moving average of $3.00 and a 200-day simple moving average of $2.88.

SAB Biotherapeutics (NASDAQ:SABS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. Equities research analysts predict that SAB Biotherapeutics, Inc. will post -3.69 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on SABS shares. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of SAB Biotherapeutics in a report on Monday, August 12th. Chardan Capital reissued a “buy” rating and set a $25.00 price objective on shares of SAB Biotherapeutics in a report on Thursday, November 7th. Oppenheimer reissued an “outperform” rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a report on Thursday, September 12th. Finally, Craig Hallum began coverage on shares of SAB Biotherapeutics in a report on Wednesday, October 9th. They set a “buy” rating and a $11.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SAB Biotherapeutics presently has an average rating of “Buy” and a consensus target price of $12.40.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.